Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (ri(n).r(c(12)u)n)
2. Ampligen
3. Mismatched Double-stranded Rna
4. Poly(i)-poly(c12u)
5. Poly(i).poly(c12,u)
6. Poly(inosinic Acid) Poly(cytidylic(12), Uridylic)acid
1. 38640-92-5
2. [(2r,3s,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl Dihydrogen Phosphate;[(2r,3s,4r,5r)-3,4-dihydroxy-5-(6-oxo-1h-purin-9-yl)oxolan-2-yl]methyl Dihydrogen Phosphate;[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl Dihydrogen Phosphate
3. Schembl27306
4. Dtxsid50191952
Molecular Weight | 995.6 g/mol |
---|---|
Molecular Formula | C28H40N9O25P3 |
Hydrogen Bond Donor Count | 15 |
Hydrogen Bond Acceptor Count | 27 |
Rotatable Bond Count | 12 |
Exact Mass | 995.13481879 g/mol |
Monoisotopic Mass | 995.13481879 g/mol |
Topological Polar Surface Area | 517 Ų |
Heavy Atom Count | 65 |
Formal Charge | 0 |
Complexity | 1600 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 12 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
Antiviral Agents
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)
ABOUT THIS PAGE
A Rintatolimod manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rintatolimod, including repackagers and relabelers. The FDA regulates Rintatolimod manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rintatolimod API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Rintatolimod supplier is an individual or a company that provides Rintatolimod active pharmaceutical ingredient (API) or Rintatolimod finished formulations upon request. The Rintatolimod suppliers may include Rintatolimod API manufacturers, exporters, distributors and traders.
Rintatolimod Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rintatolimod GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Rintatolimod GMP manufacturer or Rintatolimod GMP API supplier for your needs.
A Rintatolimod CoA (Certificate of Analysis) is a formal document that attests to Rintatolimod's compliance with Rintatolimod specifications and serves as a tool for batch-level quality control.
Rintatolimod CoA mostly includes findings from lab analyses of a specific batch. For each Rintatolimod CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rintatolimod may be tested according to a variety of international standards, such as European Pharmacopoeia (Rintatolimod EP), Rintatolimod JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rintatolimod USP).
LOOKING FOR A SUPPLIER?